Hale Therapeutics

Hale Therapeutics

Closed: Jul. 2022

About this raise

Hale Therapeutics, with a valuation of $15 million, is raising funds on SeedInvest. The company has developed its proprietary medical vaporizer and mobile app that helps smokers quit nicotine more easily. The dual-capsule solution of Hale Therapeutics is disrupting current nicotine replacement therapies and is designed to wean people off of nicotine with minimum withdrawal symptoms gradually. Josh Israel founded Hale Therapeutics in July 2018. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $1,070,000. The campaign proceeds will be used for preclinical testing, clinical trials, and GMP manufacturing setup.

Expand

Investment Overview

Not Funded: $26,500

Deal Terms

Total Commitments

Platform
SeedInvest
Start Date
02/28/2022
Close Date
07/13/2022
Min. Goal
$25,000
Max Goal
$1,070,000
Min. Investment

$1,000

Security Type

Convertible Note

Company Stage

Early Stage

SEC Filing Type

RegCF / RegD 506(c)    Open SEC Filing

Valuation Cap

$15,000,000

Discount

20%

Company & Team

Company

Year Founded
2018
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2C
Margin
Medium
Capital Intensity
Low
Location
Philadelphia, Pennsylvania
Business Type
High Growth
Company Website
Visit Website

Team

Employees
2
Prior Founder Exits?
Yes
Founder Name
Josh Israel
Title
CEO
Founder Name
Devin Serago
Title
COO

Financials

 Revenue
$0
 Monthly Burn
$53,441
 Runway
14.2 months

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-641,293

$-430,338

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$757,219

$721,754

Accounts Receivable

$49,551

$68,982

Total Assets

$852,260

$796,426

Short-Term Debt

$1,962,128

$1,265,078

Long-Term Debt

$0

$0

Total Liabilities

$1,962,128

$1,265,078

Create a free account today to gain access to Kingscrowd analytics and financials.

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Company Funding & Growth

Funding history

Total Prior Capital Raised
$1,980,000
VC Backed?
Yes
Close Date Platform Valuation Total Raised Security Type Status Reg Type
07/13/2022 SeedInvest $15,000,000 $26,500 Convertible Note Not Funded RegCF / RegD 506(c)
Create a free account today to gain access to Kingscrowd analytics.

Founder Interview

Hale Therapeutics Founder Josh Israel Is Determined to Help Smokers Quit

Once upon a time, cigarette companies marketed their products with the promises of healing properties and the trustworthy faces of dentists, babies, and Santa Claus. Today the health consequences of smoking tobacco are well known, and most smokers want to quit. But despite modern advancements in medicine and technology, quitting success rates remain dismally low.

Hale Therapeutics is on a mission to help smokers quit with a new method: smoking. The company has created a patented dual-capsule vaporizer that will gradually ease smokers off of nicotine with steps that may be familiar to them. We reached out to co-founder and CEO Josh Israel to learn about the origin of Hale Therapeutics and where the company might go from here.

Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.

Read Founder Interview

Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
Hale Therapeutics on SeedInvest 2022
Platform: SeedInvest
Security Type: Convertible Note
Valuation: $15,000,000

Follow company

Follow Hale Therapeutics on SeedInvest 2022

Buy Hale Therapeutics's Deal Report

Warning: according to the close date for this deal, Hale Therapeutics may no longer be accepting investments.

Hale Therapeutics Deal Report

Get Kingscrowd's comprehensive report on Hale Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Hale Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Hale Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge